50% off Premium Yearly
BMO EqWt US HthCare Hedged CADZUH.TOTOP PICKFeb 17, 2015Stock price when the opinion was issued
As of Jun 11, 2026. Market Open.
Equal weight avoids concentration in mega-pharma. Pharma, biotech, healthcare services. Lower volatility sector, so it helps diversify against the narrow leadership in the indexes right now. Defensive growth, steady demand in the area, strong balance sheets, low economic sensitivity. Good valuations.
Kicker is lots of healthcare innovation coming due to AI, and this will be a huge benefit.
Disclosure: Owns this for clients via the futures market. Though he may own similar exposure at times, he doesn't own the individual ETF. His team creates the exposure in a different way.
They use a covered call strategy to enhance the yield. Those who want exposure to healthcare space but want higher yield, it is a good option. If yield is not a concern for you, you're better off with ZUH.
Billy Kawasaki’s Insights - Picks from 5i Research. Healthcare is likely to be a strong performer in the next five years. Subsectors like medical devices, telemedicine and therapeutics should lead. A good ETF for US exposure. Unlock Premium - Try 5i Free
He does not own this one. They have an effective covered call strategy and has no issues with the fund at all. He prefers ZUH, where it is not impeded with calls being written.
60 names, equally weighted. Prefers names like JNJ, Bristol Myers, UNH, or Merck. His ETF strategy is VHT in US dollars, with more exposure to larger names. Healthcare will be choppy, but it's cheap. Demographics are in its favour.
This has more health care in it, rather than pharmaceuticals. FT AlphaDEX US Health Care (FHH-T) is a rule based ETF in the healthcare area, but they use the Russell 1000, drilling down a little bit more into some of the smaller and less recognizable companies. With this one he is not buying a US health care with an impoverished Cdn$.